Emicizumab in Acquired Hemophilia A


This study is an international, multicenter, open-label, single arm, prospective clinical trial and will evaluate the efficacy of prophylactic emicizumab administered on a scheduled basis to prevent bleeds in patients with acquired hemophilia A (AHA).

Full Title of Study: “Emicizumab in Patients With Acquired Hemophilia A: Multicenter, Single-arm, Open-label Clinical Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: September 2023


  • Drug: Emicizumab Injection
    • All eligible patients with AHA will receive the same study medication consisting of once weekly subcutaneous emicizumab. For each subject, the maximal duration of the study will be 24 weeks including 12 weeks treatment with emicizumab and 12 weeks Immunosuppressive therapy according to local standard of care.

Arms, Groups and Cohorts

  • Experimental: Treatment with emicizumab

Clinical Trial Outcome Measures

Primary Measures

  • The number of clinically significant bleeds per patient-week until death or week 12 after starting emicizumab treatment, whatever occurs first
    • Time Frame: 12 weeks

Secondary Measures

  • Incidence and severity of adverse events, thromboembolic events, thrombotic microangiopathy in the 12 weeks after starting emicizumab
    • Time Frame: 12 weeks
  • Incidence of mortality and cause of death in the 24 weeks after starting emicizumab treatment
    • Time Frame: 24 weeks
  • Days of treatment with and total dose of bypassing agents (recombinant factor VIIa, activated prothrombin complex concentrate) or recombinant porcine factor VIII (susoctocag alfa) or other factor VIII concentrates
    • Time Frame: 24 weeks
  • Days in hospital during 12 weeks of emicizumab treatment
    • Time Frame: 12 weeks
  • Number of patients achieving partial remission in the 24 weeks after starting emicizumab treatment
    • Time Frame: 24 weeks

Participating in This Clinical Trial

Inclusion Criteria

  • Patients diagnosed with AHA based on a reduced FVIII activity (<50 %) and positive FVIII inhibitor (>0.6 BU/ml) at screening (local laboratory) – Signed informed consent form by the participant or a Person who is legally authorized to sign on behalf of the participant before any study specific tests or procedures are done – Male or female patients aged 18 years or older at the time of informed consent – Ability to understand and follow study-related instructions – Current bleeds due to AHA at the time of screening Exclusion Criteria:

  • Congenital hemophilia A – Treatment with aPCC within the last 48 h before first study treatment or planned treatment with aPCC during the course of the study – Treatment of AHA within the days before study enrollment with more than 100 mg prednisolone (or equivalent) per day or prednisolone for more than 2 days or with other immunosuppressive drugs (e.g. rituximab, cyclophosphamide). IST for other concomitant disorders (e.g. autoimmune disorders) is not an exclusion criterion and can be continued at the investigator's discrétion – Therapy (current or planned during the emicizumab treatment period) with immunospuppressive or immune modulating drugs that were not already given on a regular basis before first diagnosis of AHA – Positive lupus anticoagulant at the time of screening – Severe uncontrolled infection at the time of screening – Signs of active disseminated intravascular coagulation at the time of screening – Current treatment for thromboembolic disease or signs of current thromboembolic disease at time of screening – Patients who are at high risk for TMA (e.g., have a previous medical or family history of TMA), in the investigator's judgment – Known severe congenital or acquired thrombophilia – Life expectancy <3 months at the time of screening – Other conditions that substantially increase risk of bleeding or thrombosis by the discretion of the investigator – Contraindications according to the local SmPC of emicizumab (see 16.1 Appendix I) – Current treatment with emicizumab at time of screening – History of clinically significant hypersensitivity associated with monoclonal antibody therapies or components of the emicizumab injection by the discretion of the investigator – Concurrent disease, treatment, or abnormality in clinical laboratory tests that could interfere with the conduct of the study, may pose additional risk, or would, in the opinion of the local investigator, preclude the patient's safe participation in and completion of the study – Addiction or other diseases that preclude the patient from appropriately assessing the nature and scope as well as possible consequences of the clinical study by the discretion of the investigator – Pregnant or breast-feeding women – Women of childbearing potential unless women who meet the following criteria: 1. Post-menopausal (12 months natural amenorrhea or 6 months amenorrhea with serum FSH > 40 U/mL) 2. Postoperatively (six weeks after bilateral ovariectomy with or without hysterectomy) 3. Regular and correct use of a contraceptive method with error rate <1% per year such as implants, depot injections, oral contraceptives or intrauterine devices 4. Sexual abstinence 5. Vasectomy of the partner – Men of sexual activity with women of childbearing potential who are not willing to use an effective barrier method of contraception during and up to 3 months after the end of therapy – Subject is in custody by order of an authority or a court of law – Receipt of an investigational drug concurrently or within 5 half-lives before administration of the study drug

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • GWT-TUD GmbH
  • Collaborator
    • Hoffmann-La Roche
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Andreas Tiede, Prof. Dr., Study Director, Hannover Medical School
  • Overall Contact(s)
    • GWT-TUD GmbH, +49 (0) 351 25933 100, medical.consulting@gwtonline.de

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.